YiChang HEC ChangJiang Pharmaceutical Statistics

Total Valuation

YiChang HEC ChangJiang Pharmaceutical has a market cap or net worth of HKD 7.74 billion. The enterprise value is 8.62 billion.

Market Cap	7.74B
Enterprise Value	8.62B

Important Dates

The next estimated earnings date is Friday, November 29, 2024.

Earnings Date	Nov 29, 2024
Ex-Dividend Date	n/a

Share Statistics

YiChang HEC ChangJiang Pharmaceutical has 879.97 million shares outstanding.

Shares Outstanding	879.97M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.05%
Owned by Institutions (%)	4.22%
Float	405.32M

Valuation Ratios

The trailing PE ratio is 4.38 and the forward PE ratio is 4.30.

PE Ratio	4.38
Forward PE	4.30
PS Ratio	1.30
PB Ratio	0.83
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 3.17, with an EV/FCF ratio of -103.92.

EV / Earnings	4.87
EV / Sales	1.45
EV / EBITDA	3.17
EV / EBIT	3.75
EV / FCF	-103.92

Financial Position

The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.27.

Current Ratio	2.15
Quick Ratio	1.34
Debt / Equity	0.27
Debt / EBITDA	0.92
Debt / FCF	-30.30
Interest Coverage	14.74

Financial Efficiency

Return on equity (ROE) is 19.25% and return on invested capital (ROIC) is 11.83%.

Return on Equity (ROE)	19.25%
Return on Assets (ROA)	10.30%
Return on Capital (ROIC)	11.83%
Revenue Per Employee	1.22M
Profits Per Employee	362,016
Employee Count	4,618
Asset Turnover	0.43
Inventory Turnover	2.50

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +40.35% in the last 52 weeks. The beta is 0.11, so YiChang HEC ChangJiang Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.11
52-Week Price Change	+40.35%
50-Day Moving Average	9.26
200-Day Moving Average	9.82
Relative Strength Index (RSI)	46.25
Average Volume (20 Days)	3,275,160

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, YiChang HEC ChangJiang Pharmaceutical had revenue of HKD 5.95 billion and earned 1.77 billion in profits. Earnings per share was 2.01.

Revenue	5.95B
Gross Profit	4.70B
Operating Income	2.30B
Pretax Income	1.80B
Net Income	1.77B
EBITDA	2.71B
EBIT	2.30B
Earnings Per Share (EPS)	2.01

Full Income Statement

Balance Sheet

The company has 1.64 billion in cash and 2.51 billion in debt, giving a net cash position of -876.97 million or -1.00 per share.

Cash & Cash Equivalents	1.64B
Total Debt	2.51B
Net Cash	-876.97M
Net Cash Per Share	-1.00
Equity (Book Value)	9.31B
Book Value Per Share	10.58
Working Capital	3.15B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 486.55 million and capital expenditures -569.51 million, giving a free cash flow of -82.96 million.

Operating Cash Flow	486.55M
Capital Expenditures	-569.51M
Free Cash Flow	-82.96M
FCF Per Share	-0.09

Full Cash Flow Statement

Margins

Gross margin is 78.90%, with operating and profit margins of 38.58% and 29.74%.

Gross Margin	78.90%
Operating Margin	38.58%
Pretax Margin	30.30%
Profit Margin	29.74%
EBITDA Margin	45.47%
EBIT Margin	38.58%
FCF Margin	-1.39%

Dividends & Yields

YiChang HEC ChangJiang Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on June 9, 2020. It was a forward split with a ratio of 2.

Last Split Date	Jun 9, 2020
Split Type	Forward
Split Ratio	2

Scores

YiChang HEC ChangJiang Pharmaceutical has an Altman Z-Score of 2.98. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.98
Piotroski F-Score	n/a